The power of the placebo effect in diabetes: A systematic review and meta-analysis.

Autor: Gossenheimer AN; Department of Internal Medicine, Faculty of Medicine, Graduate Program in Medical Sciences: Endocrinology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. Electronic address: ag.far@hotmail.com., de Freitas MB; Pharmacy College, Federal University of Rio Grande do Sul, Porto Alegre, Brazil., Pádua Borges R; Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil., Pohlmann L; School of Pharmacy in UniRitter, Porto Alegre, Brazil., Dalzochio M; Health Department of the Municipality of Caxias do Sul, Brazil., Todendi P; Department of Internal Medicine, Faculty of Medicine, Graduate Program in Medical Sciences: Endocrinology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil., Ziegelmann PK; Department of Statistics and the Postgraduate Program in Cardiology and Cardiovascular Sciences at Federal University of Rio Grande do Sul, Porto Alegre, Brazil., Telo GH; School of Medicine, Graduate Program in Medicine and Health Sciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil., Schaan BD; Department of Internal Medicine, Faculty of Medicine, Graduate Program in Medical Sciences: Endocrinology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Jazyk: angličtina
Zdroj: Primary care diabetes [Prim Care Diabetes] 2023 Jun; Vol. 17 (3), pp. 221-228. Date of Electronic Publication: 2023 Mar 30.
DOI: 10.1016/j.pcd.2023.03.006
Abstrakt: This review aims to identify the magnitude of the placebo effect in people with type 2 diabetes mellitus. Literature research was conducted Medline, Embase and Virtual Health Library for studies published between the date of inception and June 2021. The eligibility criteria included randomized controlled trials, showing comparison to placebo, having participants with type 2 diabetes mellitus, and having glycated hemoglobin (HbA1c) as the primary outcome. Meta-analysis was conducted with the effect of changing HbA1c in relation to the baseline. Exploration of heterogeneity was performed.The meta-analysis showed an increase in the average of HbA1c compared to the baseline of 0.14% (95% CI: 0.07-0.21). There was a significant difference between follow-up times (p = 0.03) and between administration routes (p = 0.01), with an increase in HbA1c in the oral route [0.15% (95% CI: 0.07-0.23)]. The meta-regression of the year of publication showed a significant downward trend (p = 0.01) of the increase in HbA1c compared to the baseline.In this study, the expected placebo effect of Hba1c reduction was not found; instead, higher Hba1c levels were observed in the control groups, although this effect was reduced over the years. Registration: PROSPERO ID CRD42020172797.
Competing Interests: Conflict of interest None.
(Copyright © 2023. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: